Djillali Annane
Expertise in
20
conditions

Djillali Annane

Garches, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
20
conditions
Garches, FR 

Overview

Djillali Annane practices practicing medicine in Garches, France.

Mr. Annane is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Sepsis, COVID-19, Myasthenia Gravis, Hepato-Pancreato-Biliary Surgery, and Thrombectomy.

He is actively involved in clinical research, co-authoring 401 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Garches, France
Other Locations
Montigny-sur-loing, France
Paris, France
Versailles, France
Hendaye, France
Villejuif, France
Creteil, France
Boulogne-billancourt, 92100, France
Saint-aubin-les-forges, France
Nimes, France
Besancon, France
104. Boulevard Raymond Poincaré, Garches, 92380, Irles, France
Raymond, 92380, France
Saint-quentin-le-verger, France
INSERM U1173, University Of Versailles St Quentin, INSERM U1028, CNRS UMR5292, Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Enrollment Status: Recruiting
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drug: Levosimendan
Study Phase: Phase 3
Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: February 09, 2026
Intervention Type: Procedure
Study Phase: Phase 3
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drug: Hydrocortisone
Study Phase: Phase 3
Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock
Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock
Enrollment Status: Unknown
Publish Date: August 31, 2023
Intervention Type: Drug
Study Drug: Esmolol
Study Phase: Phase 2
Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.
Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.
Enrollment Status: Terminated
Publish Date: February 06, 2023
Intervention Type: Drug
Study Phase: Phase 2
Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections
Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections
Enrollment Status: Completed
Publish Date: August 19, 2021
Intervention Type: Drug
Study Drug: Human Immunoglobulin
Study Phase: Phase 3
Cough Determinants in Mechanically Ventilated Patients: a Physiological Study
Cough Determinants in Mechanically Ventilated Patients: a Physiological Study
Enrollment Status: Completed
Publish Date: April 22, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 6 Less Clinical Trials

400 Total Publications

Predictive modeling of corticosteroids sensitivity in sepsis using a supervised learning approach.
Predictive modeling of corticosteroids sensitivity in sepsis using a supervised learning approach.
Journal: Journal of applied statistics
Published: September 03, 2026

Frequently Asked Questions about Djillali Annane

Is Djillali Annane a top-rated expert for Sepsis?

MediFind is an objective health platform that identifies experts based on real-world data. Djillali Annane is classified as an Elite expert for Sepsis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Djillali Annane participate in research or clinical trials?

Yes. Djillali Annane has published 400 articles and abstracts on conditions like Sepsis. You can view a list of Djillali Annane's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Annane's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 11 Advanced Conditions
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile